mufa 17:1 c

MUFA 17:1 c, also known as cis‑heptadecenoic acid, is a monounsaturated fatty acid with 17 carbon atoms and one cis double bond at the 17th carbon position. Monounsaturated fatty acids (MUFAs) are a class of fatty acids characterized by a single double bond in their hydrocarbon chain, which gives them distinct physical and metabolic properties compared with saturated and polyunsaturated fatty acids. MUFAs are liquids at room temperature and are found in various plant and animal fats. Cis‑heptadecenoic acid is a minor MUFA in most foods, contributing a small proportion to total monounsaturated fat intake. It is biosynthesized in small amounts in bacterial processes and present at low levels in dairy fats and certain animal tissues. Because it is a minor component, most nutritional databases do not provide extensive data on it specifically, instead reporting total monounsaturated fat content. MUFAs including oleic acid, palmitoleic acid, and vaccenic acid are more extensively studied, whereas MUFA 17:1 c has limited direct research. MUFAs are structurally defined by a single double bond (unsaturation) that influences fluidity of cell membranes and affects lipid metabolism. The cis configuration causes a bend in the fatty acid chain, affecting enzymatic interactions and incorporation into triglycerides and phospholipids. In the diet, MUFAs are typically consumed as part of triglycerides in oils, nuts, seeds, and animal fats. Dietary patterns rich in MUFAs, such as the Mediterranean diet, have been a focus of research because of associations with favorable health outcomes. While cis‑heptadecenoic acid itself has not been the subject of targeted research, understanding MUFAs broadly provides context for its presence as a dietary component.

Monounsaturated fatty acids (MUFA), the category that includes MUFA 17:1 c, contribute to multiple aspects of human metabolism. MUFAs are incorporated into cell membrane phospholipids and triglycerides, affecting membrane fluidity and cell signaling. A substantial body of evidence suggests that diets higher in MUFAs and lower in saturated fats are linked with improved lipid profiles, including reductions in low‑density lipoprotein (LDL) cholesterol when replaced for saturated fats, although specific effects vary by fatty acid type. A 2022 meta‑analysis of randomised controlled trials investigating MUFA‑rich foods reported modulation of blood lipid profiles, with increases in high‑density lipoprotein (HDL) cholesterol and reductions in triglycerides for certain MUFA sources, suggesting cardiometabolic benefits. The underlying mechanisms involve alterations in hepatic lipoprotein metabolism, enhanced clearance of LDL particles, and modulation of inflammatory pathways. Substitution of MUFA for saturated fats has been associated with improved endothelial function and reduced markers of vascular inflammation in some intervention studies, although evidence for specific individual MUFAs is derived from overall MUFA intake patterns. MUFA consumption may also improve insulin sensitivity and glucose metabolism, particularly in the context of diets that replace carbohydrates or saturated fats with MUFAs. These effects may be mediated by changes in cell membrane composition affecting insulin receptor function and signaling. While MUFA 17:1 c itself lacks direct human trials, research on total MUFA intake supports a role for monounsaturated fats in cardiometabolic health. Observational studies of Mediterranean dietary patterns — high in MUFAs, particularly oleic acid — have found associations with lower incidence of cardiovascular disease, improved lipid profiles, and reduced mortality. Proposed mechanisms extend beyond lipids to include effects on oxidative stress, endothelial function, and inflammation. It is important to note that these benefits are influenced by whole dietary patterns rather than isolated fatty acids, and the specific contribution of MUFA 17:1 c remains unclear due to its minor presence in foods.

Authoritative bodies such as the NIH Office of Dietary Supplements and the FDA do not establish recommended daily allowances (RDAs) or adequate intakes (AIs) for individual fatty acids such as MUFA 17:1 c. Instead, dietary guidance focuses on total fat and total monounsaturated fat intake. Dietary reference intakes (DRIs) for total fats suggest that 20–35% of total calories come from fats, with a focus on replacing saturated fats with unsaturated fats including MUFAs and polyunsaturated fatty acids. In practical terms, health organizations recommend that most of the fats in the diet come from unsaturated sources such as vegetable oils, nuts, seeds, and fish. For individuals, this usually translates to consuming sources rich in oleic acid and other MUFAs rather than specific amounts of MUFA 17:1 c, which remains a minor component. Dietary guidelines emphasize balanced consumption of fats to support energy needs, fat‑soluble vitamin absorption, and essential fatty acids. Factors affecting individual needs include total caloric intake, age, sex, metabolic health, and presence of chronic disease. In clinical practice, focus on ratios of saturated to unsaturated fats and overall dietary quality is more meaningful than targeting specific minor fatty acids. Optimal intake of MUFAs as part of a balanced diet has been linked with better lipid profiles and cardiometabolic biomarkers in epidemiological studies. However, no blood biomarkers or deficiency criteria exist for MUFA 17:1 c, and individuals obtain it incidentally when consuming MUFA‑rich foods. Therefore, guidance to consume foods rich in monounsaturated fats — such as olive oil, avocados, and nuts — is a reasonable approach to ensuring sufficient intake of its components within a healthful diet.

There are no defined clinical deficiency symptoms specific to MUFA 17:1 c. Unlike essential fatty acids such as linoleic acid (an omega‑6) and alpha‑linolenic acid (an omega‑3), monounsaturated fatty acids can be synthesized endogenously, and there are no established deficiency states for MUFAs in humans. Clinical signs of fat deficiency more broadly — which would be relevant only in extreme malnutrition — include poor growth in infants, dry scaly skin, increased susceptibility to infection, impaired wound healing, and hormonal dysregulation. These are typically associated with overall fat insufficiency and essential fatty acid deficiency states rather than a lack of any single minor MUFA. Because MUFA 17:1 c represents a small fraction of total dietary fats, its absence is not expected to lead to specific symptoms. At‑risk populations for general fat malnutrition include individuals with severe malabsorption (e.g., cystic fibrosis, pancreatic insufficiency), those with restrictive eating disorders, and patients undergoing very low‑fat diets without medical supervision. In these groups, clinicians monitor overall fat status and essential fatty acids rather than individual MUFAs. Standard biochemical assessment does not include measurements of MUFA 17:1 c levels, and there are no established reference ranges for blood concentrations of these minor fatty acids. In practice, ensuring adequate intake of dietary fats — including sources of monounsaturated and polyunsaturated fats — supports normal physiological functions that depend on fatty acids. Healthcare providers focus on total fat intake and essential fatty acids when assessing nutritional status rather than minor components like MUFA 17:1 c, which lack clinical definitions for deficiency or optimal blood levels.

MUFA 17:1 c is a minor constituent of monounsaturated fats in foods. Therefore, foods high in monounsaturated fats provide the best sources of MUFA 17:1 c as well. Common foods rich in MUFAs include olive oil, avocado oil, macadamia nuts, and various nut and seed oils. Olive oil, especially extra virgin, is a predominant source of monounsaturated fats in diets such as the Mediterranean diet. Other oils with substantial MUFA content include canola oil, peanut oil, and high‑oleic sunflower oil. Nuts like almonds, pecans, and pistachios are rich in total monounsaturated fats and thus contain small amounts of MUFA 17:1 c. Avocados and avocado oil are also excellent MUFA sources, along with certain fish and meats that contain mixtures of fatty acids including monounsaturated types. The specific quantity of MUFA 17:1 c in these foods varies and is generally low compared with predominant MUFAs such as oleic acid. Analytical nutrient databases such as USDA FoodData Central report total monounsaturated fat content rather than individual minor fatty acids. Below is a list of common MUFA‑rich foods with their total MUFA amounts per serving, which serve as proxies for MUFA 17:1 c content.

Monounsaturated fatty acids such as MUFA 17:1 c are absorbed in the small intestine via micelle formation with bile salts; they are incorporated into chylomicrons and transported through the lymphatic system into circulation. Dietary fat absorption efficiency is high in healthy individuals, with over 90% of consumed fatty acids absorbed. Bioavailability of individual MUFAs depends on the overall fat matrix of the food and co‑consumed nutrients. For instance, dietary fiber may slightly slow fat absorption, whereas bile acid secretion is essential for efficient micelle formation. There is no evidence that MUFA 17:1 c has unique absorption pathways distinct from other MUFAs. Factors that inhibit fat absorption include conditions such as pancreatic insufficiency, bile acid deficiency (e.g., cholestatic liver disease), and medications that bind bile acids (e.g., cholestyramine), leading to fat malabsorption. Timing of fat intake relative to other macronutrients has limited effect on overall absorption but may influence postprandial lipid responses. High‑MUFA meals tend to produce gradual postprandial lipid levels compared with high saturated fat meals. In clinical settings, assessment of fat malabsorption often involves measuring fecal fat excretion rather than specific fatty acids. Because MUFAs are well absorbed and rarely the limiting nutrient, ensuring dietary fats in balanced meals supports efficient uptake of fatty acids including MUFA 17:1 c.

There are no supplements specifically for MUFA 17:1 c, nor is there evidence to support supplementation of this individual fatty acid. Instead, health organizations recommend consuming MUFA‑rich foods as part of a balanced diet. Oils high in monounsaturated fats such as olive oil and avocado oil provide a dietary source of MUFAs and have been studied in the context of overall dietary patterns. Dietary supplements that provide monounsaturated fats are typically in the form of oils, but these are not standardized for minor fatty acids like MUFA 17:1 c. When considering fat intake, focus on whole food sources and dietary patterns rather than isolated components. Individuals with conditions affecting fat metabolism or absorption should seek guidance from healthcare professionals to manage total fat intake. For most people, obtaining fats from foods rather than supplements ensures intake of a variety of beneficial nutrients.

No tolerable upper intake level has been established for MUFA 17:1 c specifically. Excess intake of total fats, including MUFAs, can lead to increased caloric intake and potential weight gain if not balanced with energy expenditure. There is no evidence of direct toxicity from MUFAs at typical dietary levels, and diets high in monounsaturated fats have been consumed safely in numerous populations, such as those adhering to Mediterranean dietary patterns. Unlike certain long‑chain polyunsaturated fatty acids where theoretical concerns exist about oxidation at very high doses, MUFAs are relatively stable. Nonetheless, extremely high intake of any fat could contribute to dysregulated lipid profiles if coupled with high saturated fat intake and sedentary lifestyles. Therefore, moderation and balance within total caloric and fatty acid recommendations are advisable.

There are no known direct drug interactions with MUFA 17:1 c itself. However, dietary fats in general can influence the absorption of certain medications. High‑fat meals may increase the bioavailability of lipophilic drugs, whereas fat‑binding medications such as orlistat can reduce fat absorption. Bile acid sequestrants such as cholestyramine may interfere with absorption of fat‑soluble vitamins and fats, potentially affecting overall fatty acid status. Patients on lipid‑lowering medications such as statins should follow dietary advice emphasizing unsaturated fats in place of saturated fats, as part of cardiovascular risk management, but this reflects overall diet rather than specific interactions with MUFA 17:1 c.